# Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin

> **NCT03510000** · NA · COMPLETED · sponsor: **Samuel Lunenfeld Research Institute, Mount Sinai Hospital** · enrollment: 30 (actual)

## Conditions studied

- Type1diabetes

## Interventions

- **DRUG:** Empagliflozin 25mg
- **DEVICE:** Single hormone artificial pancreas
- **BEHAVIORAL:** Meal strategies

## Key facts

- **NCT ID:** NCT03510000
- **Lead sponsor:** Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2019-11-21
- **Final completion:** 2019-11-21
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-06-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03510000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03510000, "Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03510000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*